Evidence mapPaperPMID 35290077Full record

ArticleCirculation. Cardiovascular imaging2022

Breast Arterial Calcification: a Novel Cardiovascular Risk Enhancer Among Postmenopausal Women.

Carlos Iribarren, Malini Chandra, Catherine Lee, Gabriela Sanchez, Danny L Sam, Farima Faith Azamian, Hyo-Min Cho, Huanjun Ding, Nathan D Wong, Sabee Molloi

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Circulation. Cardiovascular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06865885 (Study of Optimal LDL-C Value Enhancement With Inclisiran in Patients With Multiple Comorbidities in Which There Are Drug-Drug Interactions Limiting LDL-C Lowering), which is not on this map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06865885 phase4recruitingstarted 2025, after this paper: background citation

Study of Optimal LDL-C Value Enhancement With Inclisiran in Patients With Multiple Comorbidities in Which There Are Drug-Drug Interactions Limiting LDL-C Lowering

Ran2025Enrolled100Registered outcomes4Posted comparisons0ConditionsCardiometabolic Syndrome, Drug Interactions, LDL-Cholersterol Lowering, Primary PreventionArmsInclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Open the trial in the graph
3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Carlos IribarrenKaiser Permanente Division of Research, Oakland, CA (C.I., M.C., C.L., G.S.).ORCID 0000-0001-5622-1839
Malini ChandraKaiser Permanente Division of Research, Oakland, CA (C.I., M.C., C.L., G.S.).
Catherine LeeKaiser Permanente Division of Research, Oakland, CA (C.I., M.C., C.L., G.S.).
Gabriela SanchezKaiser Permanente Division of Research, Oakland, CA (C.I., M.C., C.L., G.S.).
Danny L SamKaiser Permanente Santa Clara Medical Center, CA (D.L.S.).ORCID 0000-0002-4056-1107
Farima Faith AzamianDepartment of Radiological Sciences, University of California Irvine School of Medicine (F.F.A., H.D., S.M.).ORCID 0000-0002-7158-4678
Hyo-Min ChoMedical Measurement Team, Korea Research Institute of Standards and Science, Daejeon, South Korea (H.-M.C.).ORCID 0000-0001-6395-722X
Huanjun DingDepartment of Radiological Sciences, University of California Irvine School of Medicine (F.F.A., H.D., S.M.).
Nathan D WongDivision of Cardiology, Department of Medicine and Department of Epidemiology, University of California Irvine (N.D.W.).
Sabee MolloiDepartment of Radiological Sciences, University of California Irvine School of Medicine (F.F.A., H.D., S.M.).
Kaiser Permanente · USUniversity of California, Irvine · USKaiser Permanente Santa Clara Medical Center · USKorea Research Institute of Standards and Science · KR

Funding

NHLBI NIH HHS R01 HL106043NHLBI NIH HHS R01 HL140924
6 · The paper itself

Abstract

backgroundBreast arterial calcification (BAC), a common incidental finding in mammography, has been shown to be associated with angiographic coronary artery disease and cardiovascular disease (CVD) outcomes. We aimed to (1) examine the association of BAC presence and quantity with hard atherosclerotic CVD (ASCVD) and global CVD; (2) ascertain model calibration, discrimination and reclassification of ASCVD risk; (3) assess the joint effect of BAC presence and 10-year pooled cohorts equations risk on ASCVD.

methodsA cohort study of 5059 women aged 60-79 years recruited after attending mammography screening between October 2012 and February 2015 was conducted in a large health plan in Northern California, United States. BAC status (presence versus absence) and quantity (calcium mass mg) was determined using digital mammograms. Prespecified end points were incident hard ASCVD and a composite of global CVD.

resultsTwenty-six percent of women had BAC >0 mg. After a mean (SD) follow-up of 6.5 (1.6) years, we ascertained 155 (3.0%) ASCVD events and 427 (8.4%) global CVD events. In Cox regression adjusted for traditional CVD risk factors, BAC presence was associated with a 1.51 (95% CI, 1.08-2.11;

conclusionsOur results indicate that BAC has potential utility for primary CVD prevention and, therefore, support the notion that BAC ought to be considered a risk-enhancing factor for ASCVD among postmenopausal women.

Indexed as

Cardiovascular DiseasesCohort StudiesFemaleHeart Disease Risk FactorsHumansPostmenopauseRisk AssessmentRisk FactorsUnited Statesblood pressurecalibrationcardiovascular diseasecoronary artery diseasemammography

Identifiers

PMID35290077
PMCPMC8931858
OpenAlexW4220769506

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.